#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Arteriosclerosis Progressive multifocal leukoencephalopathy Anti-glomerular basement membrane disease Systemic mastocytosis Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency Infection in an immunocompromised host Langerhans cell sarcoma Congenital cystic kidney disease Chronic graft versus host disease Arterial tortuosity syndrome Neuroblastoma Acute myeloid leukaemia Burkitt's lymphoma refractory Glomerulonephritis Demyelination More trials…

    Learn about Rare Diseases

    Pulmonary fibrosis – Diagnostics Chronic granulomatous disease – Treatment Ehlers-Danlos syndrome – Treatment Rhabdoid tumour – Life with Disease Mast cell activation syndrome Acquired haemophilia – Trials in Disease Mucopolysaccharidosis I – Treatment Glycogen storage disease type V – Diagnostics Hepatic angiosarcoma – Treatment Indolent systemic mastocytosis – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Vh4524184 Zinc Sulphate Heptahydrate [11C]Az14193391 Nacystelyn Valoctocogene Roxaparvovec Selumetinib Dexchlorpheniramine Maleate Eculizumab Op-1250 Rintatolimod Thalidomide Decitabine Spiramycin Clioquinol PEGVISOMANT Oxytocin Neostigmine Methylsulfate Aavanc80-5'Hotof Indacaterol Maleate Ciclosporin A More therapies…

    Learn about Your Condition

    Coronary artery bypass Gastric cancer stage IV Prader-Willi syndrome Intervertebral disc protrusion Overweight Glycogen storage disorder Progressive supranuclear palsy Diabetic autonomic neuropathy Amyotrophic lateral sclerosis Aicardi-Goutieres syndrome Paedophilia Eye disorder Bronchostenosis Congenital myopathy Rectal cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Breast cancer recurrent

  • Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors

    Recruiting

    2 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Ds-3939A
    Belgium France Spain

  • Study on Restoring Immunotherapy Sensitivity in Advanced Triple Negative Breast Cancer Using Ceralasertib, Durvalumab, and Paclitaxel Albumin-Bound

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer recurrent
    • Breast cancer stage IV
    • Breast cancer stage III
    Investigated Drugs:
    • Ceralasertib
    • Durvalumab
    • Paclitaxel Albumin-Bound
    Italy

  • Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer recurrent
    • Breast cancer stage I
    • Breast cancer
    Investigated Drugs:
    • Capecitabine
    • Sacituzumab Govitecan
    • Carboplatin
    Austria Belgium France Germany Ireland Spain

  • Study of palbociclib with hormone therapy versus hormone therapy alone in patients with recurrent hormone receptor-positive/HER2-negative breast cancer after surgery

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer recurrent
    • HER2 negative breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Palbociclib
    Austria France Hungary Italy Spain

  • Study of Paclitaxel, Carboplatin, and Durvalumab with or without Oleclumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Breast cancer recurrent
    • Breast cancer metastatic
    • Triple negative breast cancer
    Investigated Drugs:
    • Durvalumab
    • Oleclumab
    • Carboplatin
    Belgium France

  • Study Comparing Oral Paclitaxel (DHP107) and IV Paclitaxel for Patients with Recurrent or Metastatic HER2 Negative Breast Cancer

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Breast cancer recurrent
    • Human epidermal growth factor receptor negative
    • Breast cancer metastatic
    Investigated Drugs:
    • Paclitaxel
    Hungary

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!